Trial Information
Biomarker Analysis of Gastrointestinal, Genitourinary, Sarcoma, Rare Cancer
Inclusion Criteria:
1. Patients with histologically confirmed gastrointestinal, genitourinary, sarcoma, rare
cancer
2. Written informed consent
3. body fluid derived from cancer, available for drainage and collection
Exclusion Criteria:
- patients who do not give informed consent form for research use of
biomaterials/biospecimens
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Biomarker analyses to predict treatment response in metastatic cancer
Outcome Description:
Using patient derived tumor cells, predictive biomarker analyses (DNA, RNA protein levels etc) will be assessed.
Outcome Time Frame:
3 year
Safety Issue:
No
Authority:
South Korea: Korea Food and Drug Administration (KFDA)
Study ID:
2011-07-089-013
NCT ID:
NCT01831609
Start Date:
November 2011
Completion Date:
December 2016
Related Keywords:
- Sarcoma
- Gastrointestinal
- Genitourinary
- Rare Cancer
- Sarcoma